TRADE OR INVEST wisely. WE CAN JUST PREDICT. Disclaimer: I am not a SEBI registered advisor , so before entering on my view plz ask your SEBI Registered Advisor . Profit is your and loss is your. PLEASE LIKE AND SHARE IF YOU AGREE WITH THE IDEA
UI is developing an advanced holistic addiction treatment protocol, at its Kelburn Recovery Centre, that when combined with the planned ibogaine detox methodology is expected to transform the way we treat addiction and dramatically promote the welfare of families affected by addiction.
$IBOGF is one of the most bought stocks of 2022 and is on an apparent rise on the OTC market overpowering investors on the go, the shares are trading at $0.0431 with a considerable climb.
$IBOGF is one of the most lauded stocks of all time by the investors and it has justified that remarks very well over the years. the shares are trading effectively at $0.0431 along with a major spike
Investing on $HEM and earning a huge amount of profit with less investment is the dream of every investor. $HEM is at the most opportune juncture in the market and the last closing price was $0.26 with courage and a momentous spike.
Good things are coming from Universal Ibogaine. It could be a catalyst for the entire space. $IBOGF is the ticker symbol of Universal Ibogaine Inc. listed on OTC. In the last 50 days the moving average of $IBOGF is $0.0507.
$IBO over the years have maintained a solid and supple market cap, currently the company’s market capitalization is valued over $7.57M and is mounting effectively and the shares are actively being traded on OTC at $0.0376 per unit.
Universal Ibogaine Inc. is an expanding Canadian-holding company with an average volume of $7K in the last 3 months. The average volume of the company in the last 10 days is $5.02K with $190.74M share outstanding. The stock price when the market opened was $0.0397.
Dr. Sola, a co-founder of Universal Ibogaine and a member of its Board of Directors, has effectively administered over 3,700 ibogaine treatments, more than any other doctor in the world, at an independent clinic in Cancun, Mexico, where he is a partner.
"H.C. Wainwright is a leader in the field and may be a significant strategic partner in our ongoing corporate finance roadmap," said Nick Karos, CEO of Universal Ibogaine. Another crucial step in raising awareness of our brand and service is the chance to share our story with this audience.
"The significance of this occasion cannot be emphasized," said CEO Nick Karos. This is the first gathering of academic researchers, real-world technicians, and government policymakers of its sort. This event will raise awareness of ibogaine's great potential at the highest levels."
$HMTXF today marked quite an impressive opening in the otc market and is currently trading with a steady pace at $0.1960 with a notable spike Hemostemix hires new financial advisor to the family Mr. Rick Groome who has effectively settled 2 securities firm, helping many successful biotechnology companies in providing funds over the last three decades has...
Hemostemix Inc. announced that in accordance with its stock option plan, it has granted on February 28, 2022, subject to regulatory approval, a total of 1,494,269 stock options to purchase common shares of Hemostemix to directors, officers, employees and consultants of Hemostemix
Hemostemix Inc. holds a significant role in TSX-V with its greater difference between the lower and higher range of trading today is $0.255-$0.285. In the last 52 weeks it is $0.13-$0.42.
Hemostemix Inc. is a publicly traded biotechnology company listed on TSX-V marked with an opening of $0.285.
Our mission is to redefine the addiction recovery experience, providing those living with addiction the best possible recovery. While seeking to move Ibogaine through Clinical Trials in Canada, we are building a network of holistic recovery clinics and a state of the art treatment program centred around new treatment modalities.
Universal Ibogaine Inc. is a life science company with a mission to transform addiction treatment through the use of medicalized ibogaine and a global licensing model through a planned Canadian Clinical trial.
"We are happy to have access to Blue Digital's distribution channels, as their range across borders will broaden awareness of our business to new audiences," said Nick Karos, UI's Chief Executive Officer. Because addiction knows no bounds, the remedy we seek must be global in scope." Alike Blue Digital Media’s expertise radar